Viking Therapeutics Stock Surges on Acquisition Speculation and Analyst Confidence
Published on 11/13/2025 at 09:54 | Redaktion boerse-global.de
Shares of Viking Therapeutics reached their highest point in ten months during Wednesday’s trading session, continuing a significant upward trend. The biopharmaceutical company’s promising obesity treatment pipeline has generated substantial analyst enthusiasm and intensified market talk about a potential acquisition.
The current market optimism is firmly rooted in strong clinical results. In early November, Viking presented additional positive data from its Phase 2 VENTURE trial for its lead obesity drug candidate, VK2735. An exploratory analysis revealed that treatment with VK2735 led to marked improvements in key cardiometabolic parameters for patients.
Notably, a significant proportion of patients classified as prediabetic saw their glycemic status return to normal. Furthermore, Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
